<- Go Home
Profound Medical Corp.
Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company’s lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It also provides Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. It operates in Canada, Germany, the United States, China, and Finland. Profound Medical Corp. is headquartered in Mississauga, Canada.
Market Cap
CAD 256.7M
Volume
16.4K
Cash and Equivalents
CAD 38.3M
EBITDA
-CAD 34.9M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
CAD 13.7M
Profit Margin
71.79%
52 Week High
CAD 8.93
52 Week Low
CAD 3.76
Dividend
N/A
Price / Book Value
5.15
Price / Earnings
-7.16
Price / Tangible Book Value
5.17
Enterprise Value
CAD 225.8M
Enterprise Value / EBITDA
-6.54
Operating Income
-CAD 35.4M
Return on Equity
73.53%
Return on Assets
-39.46
Cash and Short Term Investments
CAD 38.3M
Debt
CAD 7.4M
Equity
CAD 49.8M
Revenue
CAD 19.1M
Unlevered FCF
-CAD 24.8M
Sector
Health Care Equipment and Supplies
Category
N/A